重组组织型纤溶酶原激活剂治疗合并房颤的急性缺血性脑卒中患者的疗效及安全性

• 作 者: 黄银辉 林友榆 卓识途 姚力 李明媚 许盈盈 杨美丽 李隽静 张碧月 蔡若蔚
• 机 构: 福建医科大学附属第二医院晋江分院,福建医科大学附属第二医院,中国西电集团医院,福建省安溪县铭选医院,
• 出 处: 中国老年学杂志
• 发表日期: 2014年16期
• 关键词: 房颤 急性缺血性脑卒中 rt-PA 疗效 安全

目的探讨合并房颤的急性缺血性脑卒中患者组织型纤溶酶原激活剂(rt-PA)静脉溶栓的疗效及安全性。方法从2009年2月到2013年1月连续收集发病4.5 h内给予rt-PA溶栓的急性缺血性脑卒中患者作为研究对象。根据有无合并房颤将符合入选标准的病例分为房颤组和无房颤组。采用改良的Rankin量表评价神经功能恢复状况。结果两组在90 d内溶栓预后良好率、颅内出血的发生率、症状性颅内出血的发生率及死亡率无统计学差异(P>0.05)。结论两组疗效及安全性差异均无统计学意义,且对急性缺血性脑卒中患者静脉溶栓疗效无影响,rt-PA治疗合并房颤的急性缺血性脑卒中患者是安全、有效的。

Objective To investigate the efficacy and safety of intravenous thrombolysis with tissue plasminogen activator (rt-PA) in patients with acute ischemic stroke complicated with atrial fibrillation. Methods From February 2009 to January 2013, patients with acute ischemic stroke who received rt-PA thrombolysis within 4.5 hours of onset were collected continuously as study subjects. According to the presence or absence of atrial fibrillation will meet the inclusion criteria of cases were divided into atrial fibrillation group and no atrial fibrillation group. A modified Rankin scale was used to assess neurological recovery. Results There was no significant difference between the two groups in the prognosis of thrombolysis after 90 days, the incidence of intracranial hemorrhage, the incidence of symptomatic intracranial hemorrhage and the mortality (P> 0.05). Conclusion There is no significant difference between the two groups in the efficacy and safety, and has no effect on the thrombolytic efficacy in patients with acute ischemic stroke. Rt-PA is safe and effective in patients with acute ischemic stroke complicated with atrial fibrillation .